Park J, et al. - Researchers analyzed long-term prescription patterns of antithrombotic therapy in real-world clinical practice among 8,891 patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) using the National Health Insurance Service database of Korea. They included only patients with no repeated PCI or death within 2 years post-procedure. Following discharge, they examined prescription records of anticoagulants and antiplatelet agents at 3-month intervals. Findings revealed a significant number (76%) of patients with AF undergoing PCI, even in the presence of a high risk of stroke, were not prescribed oral anticoagulants (OAC) at discharge, contrary to the current guidelines. Antiplatelet agents without OAC continued to be prescribed in the majority of the patients beyond the 1-year time-point after PCI.